Moderna expands use of AI-ready R&D platform
Ella Day | May 12, 2025 | News story | Business Services, Research and Development, Technical Consultancy | AI, Benchling, Corporate, Moderna, R&D, digital transformation
Moderna has expanded its partnership with Benchling, a cloud-based research platform, to support its broader research organisation. Previously used by its technical teams, the platform will now be adopted by scientists across the company as part of efforts to streamline data management and accelerate research workflows.
The move reflects a wider shift in the biotech sector towards integrated digital systems capable of supporting artificial intelligence (AI)-driven research. Benchling allows scientists to design experiments, track samples and analyse data within a single platform, replacing a patchwork of legacy tools. This transition is intended to reduce set-up time for new workflows, enable high-throughput data processing, and standardise information for machine learning applications.
“AI is creating extraordinary opportunities in science, but realising its full potential requires entirely new ways of working,” said Wade Davis, senior vice president at Moderna. “Through this collaboration, our scientists have access to a strong foundation for AI and our computational scientists and engineers are empowered to do truly cutting-edge work.”
Benchling’s platform has also been adopted by other pharmaceutical companies, including Sanofi, AstraZeneca and Zealand Pharma to help digitise and automate aspects of R&D.
“Moderna and Benchling are showing what the future of R&D looks like – fully digital, deeply integrated and built for intelligence and scale,” said Sajith Wickramasekara, CEO and co-founder of Benchling.
Ella Day
12/5/25
Related Content
Cellbyte raises $2.75m to fund pharma drug launch platform
Cellbyte has announced that it has raised $2.75m in seed funding for the streamlining of …
MultiOmic Health and BIO4 Campus sign collaborative Memorandum of Understanding
MultiOmic Health (MOH), an artificial intelligence (AI)-enabled precision medicine biotechnology company and BIO4 Campus (BIO4), …
Sanome’s AI tool gains certification for early detection of hospital infections
Sanome’s MEMORI, an artificial intelligence (AI) medical device that can predict hospital-acquired infections up to …
